S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94

Inotiv (NOTV) Stock Forecast, Price & News

+4.59 (+38.38%)
(As of 05/13/2022 06:55 PM ET)
Today's Range
50-Day Range
52-Week Range
1.45 million shs
Average Volume
277,436 shs
Market Capitalization
$421.35 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NOTV News and Ratings via Email

Sign-up to receive the latest news and ratings for Inotiv and its competitors with MarketBeat's FREE daily newsletter.

About Inotiv

Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.


See More Headlines

Industry, Sector and Symbol

Commercial physical research
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$89.61 million
Cash Flow
$0.76 per share
Book Value
$6.60 per share


Net Income
$10.90 million
Pretax Margin




Free Float
Market Cap
$421.35 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.89 out of 5 stars

Medical Sector

706th out of 1,403 stocks

Commercial Physical Research Industry

10th out of 23 stocks

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Inotiv (NASDAQ:NOTV) Frequently Asked Questions

Is Inotiv a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inotiv in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Inotiv stock.
View analyst ratings for Inotiv
or view top-rated stocks.

When is Inotiv's next earnings date?

Inotiv is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Inotiv

How were Inotiv's earnings last quarter?

Inotiv, Inc. (NASDAQ:NOTV) posted its quarterly earnings data on Thursday, May, 12th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.40. Inotiv had a negative net margin of 29.56% and a negative trailing twelve-month return on equity of 6.07%. During the same quarter last year, the company posted ($0.06) EPS.
View Inotiv's earnings history

What guidance has Inotiv issued on next quarter's earnings?

Inotiv updated its FY 2022 earnings guidance on Thursday, May, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $510.00M-, compared to the consensus revenue estimate of $470.49 million.

What price target have analysts set for NOTV?

3 Wall Street analysts have issued 1-year price targets for Inotiv's stock. Their forecasts range from $45.00 to $75.00. On average, they anticipate Inotiv's stock price to reach $63.67 in the next year. This suggests a possible upside of 284.7% from the stock's current price.
View analysts' price targets for Inotiv
or view top-rated stocks among Wall Street analysts.

Who are Inotiv's key executives?
Inotiv's management team includes the following people:
  • Mr. Robert W. Leasure Jr., Pres, CEO & Director (Age 62, Pay $797.4k)
  • Ms. Beth A. Taylor CPA, VP of Fin. & CFO (Age 57, Pay $337.83k)
  • Dr. John E. Sagartz D.V.M., DiplomateACVP, DVM, Ph.D., Chief Strategy Officer & Director (Age 57, Pay $386.9k)
  • Dr. Peter T. Kissinger, Founder, Chairman Emeritus & Scientific Advisor (Age 77)
  • Mr. Mo Dastagir, Chief Technology Officer (Age 45)
  • Ms. Kimberly Beaty, Sr. Director of Marketing
  • Mr. William D. Pitchford, Chief HR Officer (Age 67)
  • Mr. Philip A. Downing, Sr. VP of Nonclinical Services (Age 52) (LinkedIn Profile)
  • Dr. J. Scott Daniels Ph.D., Sr. VP of DMPK
  • Mr. John Gregory Beattie DSA, Chief Operating Officer of Discovery and Safety Assessment (Age 55)
What is Inotiv's stock symbol?

Inotiv trades on the NASDAQ under the ticker symbol "NOTV."

Who are Inotiv's major shareholders?

Inotiv's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.86%), Vanguard Group Inc. (3.39%), Pembroke Management LTD (1.96%), Renaissance Technologies LLC (1.88%), Loomis Sayles & Co. L P (0.64%) and Northern Trust Corp (0.57%). Company insiders that own Inotiv stock include Gregory Cole Davis, James Harkness, John E Sagartz, John E Sagartz, John Gregory Beattie, Philip A Downing and Robert Jr Leasure.
View institutional ownership trends for Inotiv

Which major investors are selling Inotiv stock?

NOTV stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Calamos Advisors LLC, Russell Investments Group Ltd., Renaissance Technologies LLC, Lazard Asset Management LLC, JPMorgan Chase & Co., Royce & Associates LP, and Metropolitan Life Insurance Co NY.
View insider buying and selling activity for Inotiv
or view top insider-selling stocks.

Which major investors are buying Inotiv stock?

NOTV stock was purchased by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Rice Hall James & Associates LLC, BlackRock Inc., King Luther Capital Management Corp, Employees Retirement System of Texas, Qube Research & Technologies Ltd, Jackson Creek Investment Advisors LLC, and Pallas Capital Advisors LLC. Company insiders that have bought Inotiv stock in the last two years include Gregory Cole Davis, James Harkness, John E Sagartz, John Gregory Beattie, Philip A Downing, and Robert Jr Leasure.
View insider buying and selling activity for Inotiv
or or view top insider-buying stocks.

How do I buy shares of Inotiv?

Shares of NOTV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inotiv's stock price today?

One share of NOTV stock can currently be purchased for approximately $16.55.

How much money does Inotiv make?

Inotiv has a market capitalization of $421.35 million and generates $89.61 million in revenue each year. The company earns $10.90 million in net income (profit) each year or ($4.260010) on an earnings per share basis.

How many employees does Inotiv have?

Inotiv employs 2,000 workers across the globe.

What is Inotiv's official website?

The official website for Inotiv is www.inotivco.com.

How can I contact Inotiv?

Inotiv's mailing address is 2701 KENT AVENUE, WEST LAFAYETTE IN, 47906. The company can be reached via phone at (765) 463-4527, via email at [email protected], or via fax at 765-497-1102.

This page was last updated on 5/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.